Holen Sie sich die Stockscreener-App
195.16
0.07%
0.13
Handel nachbörslich:
195.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$195.03
Offen:
$194.22
24-Stunden-Volumen:
1.74M
Relative Volume:
1.24
Marktkapitalisierung:
$53.16B
Einnahmen:
$21.37B
Nettoeinkommen (Verlust:
$1.41B
KGV:
49.49
EPS:
3.9437
Netto-Cashflow:
$3.07B
1W Leistung:
+0.42%
1M Leistung:
+6.16%
6M Leistung:
+30.52%
1J Leistung:
+5.94%
1-Tages-Spanne:
$193.80
$196.88
1-Wochen-Bereich:
$193.80
$200.42
52-Wochen-Spanne:
$140.11
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, RMD, ALC, WST
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
195.16 | 53.16B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
444.18 | 156.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
RMD
Resmed Inc
|
250.17 | 35.18B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
69.83 | 33.76B | 10.63B | 819.00M | 1.59B | 1.6577 |
WST
West Pharmaceutical Services Inc
|
403.64 | 28.41B | 3.22B | 542.70M | 458.00M | 7.4805 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-20 | Eingeleitet | Wolfe Research | Outperform |
| 2026-07-28 | Eingeleitet | UBS | Buy |
| 2026-05-04 | Fortgesetzt | Evercore ISI | Outperform |
| 2026-04-10 | Fortgesetzt | Goldman | Neutral |
| 2026-02-10 | Fortgesetzt | Barclays | Overweight |
| 2026-02-03 | Fortgesetzt | Citigroup | Buy |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
Waters Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results? - Zacks Investment Research
ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus - Zacks Investment Research
DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research
Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures? - Zacks Investment Research
Becton Dickinson appoints Ferass Abuzaina as worldwide president of Surgery - scanx.trade
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock? - Zacks Investment Research
BECTON, DICKINSON AND COMPANY (4BDX.TI) latest stock news and headlines - Yahoo Finance Australia
Becton Dickinson & Co (BDX) Shares Surge 3.1% -- What GF Score o - GuruFocus
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally? - Zacks Investment Research
Becton Dickinson stock hits 52-week high at 196.42 USD - Investing.com
Becton Dickinson stock hits 52-week high at 196.42 USD By Investing.com - Investing.com Canada
BDX.GJ Bond Profile: Coupon and Redemption - TradingView
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line - Zacks Investment Research
Catholic Medical Mission Board and Church of the Brethren to mark partnership with ribbon-cutting - GlobeNewswire Inc.
Becton, Dickinson: Fundamentals Remain Solid, Trades Near Fair Value (Rating Downgrade) - Seeking Alpha
31,495 Becton, Dickinson and Company $BDX Shares Sold by Forbes J M & Co. LLP - InsuranceNewsNet
XS2839004368 Bond Yield and Price — BONDSCOM:XS2839004368 - TradingView
Becton, Dickinson and Co (BOX.MU) stock price, news, quote and history - Yahoo Finance UK
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Becton Dickinson stock hits 52-week high at 193.1 USD - Investing.com
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look? - Yahoo Finance
Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further? - Yahoo Finance
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
News | Medical-supply maker BD pledges $19 billion investment in US operations - CoStar
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Celebrating a medical milestone - Plastics News
BD strikes $19B manufacturing deal with US government - NJBIZ
Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target - Moomoo
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Becton, Dickinson and Company (BDX) Stock Forecast and Price Target 2026 $BDX - MarketBeat
Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target - Yahoo Finance
Becton Dickinson pledges $19 billion US investment in deal with government - Reuters
Becton Dickinson to Spend $3 Billion Expanding US Medical Manufacturing, Trump Says - BigGo Finance
BD to invest billions in U.S. manufacturing - Medical Design & Outsourcing
Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing - Benzinga
BD to invest $19B in the US to bring relief from future tariffs - BioWorld News
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing By Investing.com - Investing.com
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief - WSJ
BD Appoints Ferass Abuzaina as Worldwide President of Surgery – Company Announcement - Financial Times
A new leader takes charge of BD’s Surgery business immediately - Stock Titan
Becton Dickinson to invest $19 billion in US - Yahoo Finance
BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience – Company AnnouncementFT.com - Financial Times
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs L - Benzinga
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End - TradingView
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Becton Dickinson Co-Aktie (BDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MICHAEL FELD | Officer |
Oct 26 '26 |
Proposed Sale |
198.91 |
76 |
15,117 |
0 |
| Feld Michael | EVP, Chief Revenue Officer |
Sep 28 '26 |
Sale |
183.70 |
76 |
13,961 |
19,644 |
| MICHAEL FELD | Officer |
Sep 28 '26 |
Proposed Sale |
183.82 |
76 |
13,970 |
0 |
| MICHAEL FELD | Officer |
Aug 26 '26 |
Proposed Sale |
189.78 |
165 |
31,314 |
0 |
| Feld Michael | EVP, Chief Revenue Officer |
Aug 26 '26 |
Sale |
188.49 |
165 |
31,101 |
19,720 |
| RICHARD BYRD | Former Officer |
Aug 20 '26 |
Proposed Sale |
187.97 |
1,330 |
249,993 |
0 |
| Polen Thomas E Jr | Chairman, CEO and President |
Aug 13 '26 |
Sale |
185.00 |
4,152 |
768,120 |
110,163 |
| THOMAS POLEN | Director |
Aug 13 '26 |
Proposed Sale |
183.58 |
4,152 |
762,224 |
0 |
| Polen Thomas E Jr | Chairman, CEO and President |
Aug 13 '26 |
Option Exercise |
167.25 |
43,278 |
7,238,246 |
153,441 |
| Roland Goette | Officer |
Aug 11 '26 |
Proposed Sale |
180.84 |
2,438 |
440,877 |
0 |
0.25%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):